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Breast cancer fatigue (BCF) is a complex and multidimensional condition characterized
by a persistent sense of physical and/or mental stiffness, resulting in a substantial
impairment of health-related quality of life in breast cancer survivors. Aim of this
prospective cohort study was to evaluate the feasibility and the effectiveness of a 4-week
rehabilitation protocol on BCF, muscle mass, strength, physical performance, and quality
of life in breast cancer (BC) survivors. We recruited adult BC women with a diagnosis
of BCF, according to the International Classification of Diseases 10 criteria, referred
to the Outpatient Service for Oncological Rehabilitation of a University Hospital. All
participants performed a specific physical exercise rehabilitative protocol consisting of
60-min sessions repeated 2 times/week for 4 weeks. All outcomes were evaluated at
the baseline (T0), at the end of the 4-week rehabilitation treatment (T1), and at 2 months
follow up (T2). The primary outcome measure was the Brief Fatigue Inventory (BFI);
secondary outcomes included: Fat-Free Mass and Fat Mass, assessed by Bioelectrical
Impedance Analysis (BIA); Hand Grip Strength Test (HGS); Short Physical Performance
Battery (SPPB); 10-meter walking test (10 MWT); 6-min walking test (6 MWT); European
Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC
QLQ–C30). Thirty-six women (mean age: 55.17 ± 7.76 years) were enrolled in the study.
Significant reduction of BCF was observed both after the 4-week rehabilitation treatment
(T1) (BFI: 5.4± 1.6 vs. 4.2± 1.7; p= 0.004) and at the follow-up visit (T2) (BFI: 5.4± 1.6
vs. 4.4 ± 1.6; p = 0.004). Moreover, significant differences (p < 0.001) HGS, SPPB, 10
MWT, 6 MWT, and EORTC QLQ-C30 were found at T1, while at T2 all the outcome
measures were significantly different (p < 0.05) from the baseline. The rehabilitation
protocol seemed to be feasible, safe, and effective in reducing BCF, improving muscle
mass and function, and improving HRQoL in a cohort of BC survivors. The results of this
study could improve awareness of this underestimated disease, suggesting the definition
of a specific therapeutic exercise protocol to reduce BCF.
Keywords: breast cancer, quality of life, rehabilitation, fatigue, muscle strength, muscle performance, precision
medicine
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INTRODUCTION
Breast cancer is the most common cancer in women and one
of the leading causes of cancer-related death worldwide (1).
Owing to the advances in the clinical management of this tumor,
the number of long-term survivors has progressively increased
during the past four decades (1). In this scenario, health-related
quality of life has becomemore andmore important in the overall
patients’ outcome evaluation (2–6).
Cancer-related fatigue, also known as cancer fatigue, is a
highly prevalent long-term side effect among breast cancer
survivors (7, 8). This complex and multidimensional condition
is clinically characterized by a persistent sense of physical,
emotional, and/or cognitive stiffness, resulting in a substantial
impairment of health-related quality of life (7, 9). The etiology
of breast cancer fatigue (BCF) is poorly understood and
probably related to mitochondrial dysfunction, inflammation,
and increased reactive oxygen species production (8, 10, 11).
However, the wide subjectivity of BCF hinders further research to
explain its pathogenesis. Several risk factors have been identified
so far, including low socioeconomic status, sleep disturbance,
emotional stress, anxiety, physical inactivity, high body mass
index (BMI), radical surgery, chemotherapy, and radiotherapy
(8, 9). According to the American Society of Clinical Oncology
(ASCO) and the National Comprehensive Cancer Network
(NCCN) guidelines, specific screening programs for BCF should
be performed (7, 12). In this respect, the gold standard for the
evaluation of BCF is self-reporting using scales, questionnaires,
and/or inventories (13). Regrettably, the great heterogeneity
in these diagnostic methods, coupled with the lack of widely
adopted guidelines, represents a major limitation in the clinical
management of BCF (13, 14).
Several types of interventions have been proposed to treat or
reduce BCF, including counseling, psycho-education, physical
and mind-body activity, massage therapy, acupuncture,
music therapy, supplements (e.g., ginseng, vitamin D,
psychostimulants), and physical exercise (13). Among these,
the supervised physical exercise is supported by the strongest
evidence of safety and effectiveness in reducing BCF (15–19).
Nevertheless, the optimal exercise interventions scheme (i.e.,
type, combination, frequency, intensity, and duration) to reduce
BCF remains controversial. The aim of this study was to evaluate
the feasibility and effectiveness of a 4-week rehabilitation
protocol on BCF reduction.
MATERIALS AND METHODS
Patients
This prospective cohort study involved a consecutive series of
breast cancer survivors suffering from BCF. All patients referred
to the Outpatient Service for the Oncological Rehabilitation of
the Physical Medicine and Rehabilitation Unit of University
Hospital “Maggiore della Carità” in Novara, Italy over a
24-month period, from January 2018 to December 2019.
The inclusion criteria were the following: (1) diagnosis of
invasive breast cancer (2) surgery performed at least 12
months earlier; (3) diagnosis of cancer fatigue according to the
International Classification of Diseases Tenth Revision (ICD-10)
criteria. The exclusion criteria were the following: (1) anemia,
defined as hemoglobin <9 g/dl; (2) severe thrombocytopenia,
defined as platelets <100,000/mm3; (3) history of bleeding;
(4) hypothyroidism without replacement therapy; (5) persistent
insomnia; (6) central nervous system primary and/or metastatic
tumors. Inclusion and exclusion criteria are summarized in
Table 1. The study protocol was approved by the local
Institutional Review Board and was compliant with the ethical
guidelines of the responsible governmental agency. At the
enrollment, all the participants were asked to carefully read and
sign an informed written consent. The investigators provided to
protect the privacy and the study procedures according to the
Declaration of Helsinki.
Intervention
All participants were subjected to a specific physical exercise
rehabilitative protocol consisting of 10min of warm-up, 40min
of aerobic exercise (e.g., walking, cycling, rowing) and strength
training (e.g., light weightlifting), and 10min of cool-down. Each
session was repeated 2 times/week with at least 2 days of rest
for 4 weeks, under the supervision of an experienced physical
therapist. The study flow chart is shown in Figure 1. At the
end of the rehabilitation treatment, a booklet encompassing the
pictures and instructions of the previously performed exercises
was provided to the patients. To maintain the benefits obtained
during the hospital treatment, all patients were trained and
strongly encouraged to continue the exercises at home. In the case
of BCF evolution and/or worsening of general clinical conditions,
the rehabilitation treatment was stopped.
Fatigue and Physical Performance
Evaluation
At the baseline (T0), demographic and anthropometric
characteristics, cancer location and staging, as well as
pharmacologic history, have been assessed. All outcomes
were also evaluated at the end of the 4-week rehabilitation
treatment (T1), and at 2 months follow-up (T2).
Primary Outcome
The primary outcome measure was the Brief Fatigue Inventory
(BFI), a multidimensional self-report scale that assesses the
effects of fatigue on health-related quality of life originally
reported by Mendoza et al. (20, 21). This survey is composed of
nine questions scored on a 0–10 point scale. The BFI is presented
as two parts. Specifically, the first three questions rate the current,
usual, and worst levels of fatigue over the last 24 h, while the
remaining six questions are related to the impact of fatigue on
activity, mood, walking, work, relationships, and enjoyment of
life. A total BFI score is then calculated by the mean of the
nine scores, where scores 1–3 indicate slight fatigue, scores 4–6
moderate fatigue, and scores 7–10 severe fatigue.
Secondary Outcomes
The secondary outcomes were the following. (1) Body
composition in terms of fat-free mass (FFM) and fat mass
(FM) by bioelectrical impedance analysis (BIA). For this study,
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TABLE 1 | Eligibility criteria of the study population.
Inclusion criteria
(1) Diagnosis of invasive breast cancer Patients with a diagnosis of breast cancer with cancer cells that have grown through the lining
of the ducts into the surrounding breast tissue.
(2) Surgery at least 12 months earlier All patients underwent breast surgery (conservative or mastectomy) at least 12 months earlier.
(3) Diagnosis of cancer fatigue according to the International
Classification of Diseases Tenth Revision (ICD-10) criteria
The ICD-10 criteria define cancer-related fatigue (CRF) as diminished energy, an increasing
need for rest, limb heaviness, diminished ability to concentrate decreased interest in engaging
in normal activities, sleep disorder, inertia, emotional liability, perceived problems with
short-term memory, and post-exertional malaise exceeding several hours.
Exclusion criteria
(1) Severe anemia A severe decrease in hemoglobin blood levels defined by the threshold of <9 g/dl.
(2) Severe thrombocytopenia A severe decrease of thrombocyte blood levels defined by the threshold of <100,000/mm3.
(3) History of bleeding Patients that have a history of bleeding during cancer evolution.
(4) Hypothyroidism without replacement therapy An endocrine system disorders, where the thyroid produces insufficient levels of thyroid
hormone, leading to several symptoms, including fatigue.
(5) Persistent insomnia Insomnia lasting more than 1 month, that might result in increased fatigue.
(6) Central nervous system primary and/or metastatic tumors Other tumors that might affect patients.
FIGURE 1 | Study flow chart.
the BIA101 Anniversary (Akern Srl, Pontassieve, Florence, Italy)
was used. BIA evaluations were performed with patients in a
supine position, with the upper and lower limbs abducted by
about 30 and 45 degrees, respectively. The electrodes were placed
on hands and feet at a minimum distance of 5 cm and connected
to the cable with the red insulated tweezers (distal) and black
(proximal). FFM and FM were determined according to the
equation elaborated by Kyle et al. (22). (2) Handgrip strength
test (HGS), using the Jamar R© hydraulic hand dynamometer
(Sammons Preston, Rolyon, Bolingbrook, IL, USA) to assess the
isometric grip strength of the hand, according to the American
College of Sports Medicine recommendations (23). This measure
strongly correlates with global muscle strength (24). Briefly,
the test was conducted with the participant seated on a chair,
the shoulder adducted and neutral for rotation, with the elbow
flexed at 90◦, the forearm neutral for prono-supination and
wrist extension between 0 and 30◦ with 0–15 degrees of ulnar
deviation. The test was repeated three times to obtain the mean.
(3) Short physical performance battery (SPPB), a composite scale
ranging from 0 to 12, assessing walking speed, standing balance,
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and sit-to-stand performance (25, 26). (4) Ten-meter walking
test (10MWT) to assess walking speed (27). (5) 6-min walking
test (6 MWT) for the integrated response of cardiopulmonary
and musculoskeletal systems (28). (6) European Organization
for Research and Treatment of Cancer 30-item quality of life
questionnaire (EORTC QLQ–C30), a unidimensional scale
that assesses the severity of symptoms related to cancer and its
treatment, consisting of functional scales (i.e., physical, role,
cognitive, emotional, and social functioning), a global quality of
life scale, symptom scales (i.e., fatigue, nausea and vomiting, and
pain), and global health (i.e., appetite loss, diarrhea, dyspnea,
constipation, insomnia, financial impact) (29). Furthermore,
at T1, both the enrolled patients and the physical therapist
expressed their satisfaction regarding this treatment, which was
assessed using the Global perceived effect (GPE) Scale, ranging
from 1 (best satisfaction) to 7 (unsatisfaction) (30).
Statistical Analysis
Statistical analyses were performed using GraphPad Prism R©,
version 7.00 (GraphPad Software, La Jolla California USA). Due
to the low numerosity of the sample, we assumed a non-gaussian
distribution of the considered variables, as previously described
(31). Differences between single variables at different time-points
were assessed by the two-way Friedman Analysis of Variance
(ANOVA) for repeated measure and Dunn’s post hoc test. A type
I error level of 0.05 was chosen. A p-value lower than 0.05 was
considered statistically significant.
RESULTS
A total of 102 women with BCF were assessed. Among them, 48
(47%) did not meet the eligibility criteria and 18 (18%) refused
to sign the informed consent. Taken together, 36 patients were
enrolled in the study. The study flowchart is depicted in Figure 1.
Demographic and General Characteristics
of BCF Patients
The mean age at diagnosis of the 36 patients included in this
study was 55.17 ± 7.76 years. Most of the women were of
normal weight or borderline overweight (BMI = 25.15 ± 5.52
kg/m2). The rate of smokers was similar to that of the general
women population (n= 8, 22.2%). All of them underwent breast
surgery, with equal distribution between conservative and radical
surgery (n = 19, 52.7%, and n = 17, 47.3%, respectively). The
en bloc axillary dissection was performed in 16 (44.4%) patients,
while 21 (58.3%) were subjected to radiotherapy, either in the
supraclavicular fossa or in the chest wall. Breast cancer related
lymphedema was present in 12 (33.3) patients. The baseline
characteristics along with the therapeutic information are listed
in Table 2.
Reduction of BCF After Rehabilitation
Treatment
We observed a statistically significant reduction of the BCF
score after the 4-week rehabilitation treatment (T1) compared
to T0 (4.2 ± 1.7 vs. 5.4 ± 1.6; p = 0.004). Despite the small
sample size, the significance was substantially maintained at
TABLE 2 | Clinicopathologic and demographic characteristics of the patients
included in this study.
Patients (n = 36)
Age 55.17 ± 7.76 years
Body mass index (BMI) 25.15 ± 5.52 kg/m2
Smoke (n, %) 8 (22.2)
Breast surgery
Conservative (n, %) 19 (52.7)
Mastectomy (n, %) 17 (47.3)
Axillary surgery
Sentinel lymph node (n, %) 20 (55.6)
En bloc dissection (n, %) 16 (44.4)
Radiotherapy (n, %) 21 (58.3)
Chemotherapy (n, %) 26 (72.2)
Hormone therapy (n, %) 29 (80.6)
Trastuzumab (n, %) 10 (27.7)
Upper limb lymphedema (n, %) 12 (33.3)
FIGURE 2 | Differences in primary outcome measure from the baseline (T0) to
the end of 4-week rehabilitation treatment (T1) and the follow-up assessment
at 3 months from the baseline (T2). * p < 0.05; ns, non significant.
the follow-up visit (T2) (4.4 ± 1.6; p = 0.004), as showed in
Figure 2 and Table 3. However, no statistical significance was
observed between the T1 and theT2 stage. Furthermore, we found
significant differences at T1 in terms of HGS (20.1 ± 5.8 vs. 22.5
± 5.2: p < 0.001), SPPB (9.3 ± 2.0 vs. 11.3 ± 1.2; p < 0.001),
10 MWT (1.5 ± 0.3 vs. 1.8 ± 0.3; p < 0.001), 6 MWT (464.5 ±
62.9 vs. 554.1 ± 71.6; p < 0.001), EORTC QLQ-C30 Functional
score (69.2± 14.9 vs. 76.9± 15.7; p < 0.001), EORTC QLQ-C30
Symptoms score (29.2 ± 14.9 vs. 21.2 ± 16.0: p < 0.001), and
EORTC QLQ-C30 Global Health score (40.7 ± 12.5 vs. 67.6 ±
14.8; p < 0.001). At 2 months (T2), all the outcome measures
significantly differ from the baseline (p < 0.05), including FFM
(43.2 ± 6.4 vs. 45.5 ± 6.6; p < 0.001) and FM (24.0 ± 10.6 vs.
21.7± 10.0; p< 0.001), as showed by Table 3. Moreover, the GPE
score measured at T1 was 2.20 considering patients’ perspective
and 2.40 considering physical therapists’ perspective.
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TABLE 3 | Differences in outcome measures from baseline (T0) to the end of 4-week rehabilitation treatment (T1) and the follow-up assessment at 3 months from the
baseline (T2).
T0 T1 T0-T1 P-value T2 T0-T2 P-value
BFI 5.4 ± 1.6 4.2 ± 1.7 0.004 4.4 ± 1.6 0.004
FFM (kg) 43.2 ± 6.4 44.4 ± 6.2 0.231 45.5 ± 6.6 <0.001
FM (kg) 24.0 ± 10.6 22.9 ± 10.2 0.297 21.7 ± 10.0 <0.001
HGS (kg) 20.1 ± 5.8 22.5 ± 5.2 <0.001 21.7 ± 6.0 0.012
SPPB 9.3 ± 2.0 11.3 ± 1.2 <0.001 11.7 ± 0.5 <0.001
10 MWT (m/s) 1.5 ± 0.3 1.8 ± 0.3 <0.001 1.9 ± 0.3 <0.001
6 MWT (m) 464.5 ± 62.9 554.1 ± 71.6 <0.001 567.1 ± 82.7 <0.001
EORTC QLQ-C30
Functional score 69.2 ± 14.9 76.9 ± 15.7 <0.001 75.0 ± 17.1 0.005
Symptoms score 29.2 ± 14.9 21.2 ± 16.0 <0.001 21.9 ± 18.5 <0.001
Global Health score 40.7 ± 12.5 67.6 ± 14.8 <0.001 65.2 ± 20.0 <0.001
BFI, Brief Fatigue Inventory; FFM, fat-free mass; FM, fat mass; HGS, hand-grip strength test; SPPB, Short Physical Performance Battery; 10 MWT, 10-min walking test; 6 MWT, 6-min
walking test; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire.
DISCUSSION
Several exercise programs have been proposed to reduce BCF (17,
32–36). However, the choice of themost appropriate intervention
to offer remains troubled in real-life clinical practice. Here,
we subjected an exploratory cohort of breast cancer survivors
suffering from BCF to a physical exercise rehabilitative protocol
consisting of 10min of warm-up, 40min of aerobic exercise
and strength training, and 10min of cool-down, twice a week
for 4 weeks. Taken together, a significant decrease of BCF was
observed at the end of the program and was maintained at the
follow-up visits.
To date, there is still little evidence about the multifactorial
mechanisms underpinning BCF pathogenesis. Historically, the
loss of muscle mass, metabolism disorders and ATP production
impairment have been viewed as founder events (37). In our
study, we noticed a significant improvement in the FFM and
a significant reduction of the FM at a 2-months follow-up but
not at T1, suggesting that muscle mass modifications need more
time to manifest compared to the relatively fast improvement of
all the functional outcomes assessed. These results highlight that
rehabilitative physical exercise counters the main mechanisms
underpinning BCF and might be considered as an effective
and reliable treatment option. This notion, however, should be
considered in the context of the small sample size investigated in
the present work.
A recent randomized controlled trial investigated the effects of
a specific training program to modulate systemic inflammation
(38). After this intervention, serum levels of TNF-α, IL-6, and IL-
10 were significantly lower in the intervention group, confirming
the anti-inflammatory properties of physical exercise previously
demonstrated in several pathological conditions (39–42) and
suggesting a possible mechanism through which it intervenes in
countering BCF clinical manifestations. Of note, given the lack
of adverse events in our study group, we confirm the excellent
safety profile of this physical exercise intervention. This approach
proved to be feasible, considering the high treatment adherence
(i.e., no dropouts) and the high GPE scores obtained by both
patients and physical therapists.
The skeletal muscle system has been recently hypothesized to
have a key role in fatigue pathogenesis (43, 44). Furthermore,
there are multiple examples in literature on the direct
mitochondria damage, inducing a dysfunction characterized by
an increased intracellular oxidative stress and low energy supply
(8, 45–48). Noteworthy, exercise training could remodel the
mitochondrial network, influencing the mitochondria intrinsic
plasticity through different mechanisms and modulating their
shape in response to fission and fusion events (45, 47, 49–51).
Furthermore, it has been recently proved that physical exercise is
able to improve mitochondrial function and dynamics in fragile
patients (51). Similarly, an endurance exercise protocol could
have a key role in the prevention ofmuscle wasting by stimulating
mitochondrial dynamics. Taken together, all these findings,
coupled with our preliminary observations, could suggest that
exercise therapy might have a crucial impact not only in the
clinical and therapeutic management of BCF, but also interfering
directly in its pathogenesis.
This study has several limitations. First, the relatively small
sample size of women with BCF included in the study could have
limited the clinical impact of our conclusions. It should be noted,
however, that our pilot prospective study provides for the first
time in literature evidence on the possible clinical application of
a specific physical exercise rehabilitative treatment in this setting.
Further prospective studies embracing larger cohorts of patients
are warranted to define the implications of our observations.
Second, due to the study design, we did not collect any data
on bone mineral density, falls, and fracture rate. Indeed, a high
prevalence (80.6%) of patients treated with aromatase inhibitor
therapy, a well-known risk factor for osteoporosis (52), has been
recruited in the present study. Considering the beneficial effects
of physical exercise on bone mineral density in premenopausal
and postmenopausal women (53), the improvement of all
functional parameters that we observed after a 1-month protocol
might constitute the basis for a possible role in contrasting
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osteoporosis, reducing the risk of falling and consequently the
risk of fragility fractures. On the other hand, given that these
women are at high risk of osteoporosis, it is mandatory to
underline the role of an adequate therapeutic exercise to prevent
fractures and all the disabling consequences. Third, the lack of a
control group limits the translational relevance of our hypothesis.
However, this study should be considered a proof-of-principle
that rehabilitation interventions can be safety and effectively
performed in breast cancer survivors. Lastly, we did not provide
any data on long-term outcomes because all of the patients
enrolled in this prospective study are still followed up by our
multidisciplinary team.
Despite these limitations, we provide preliminary and
previously unavailable evidence on the feasibility, reliability,
and safety of a 1-month specific physical exercise rehabilitative
protocol in reducing BCF, improving muscle mass, muscular-
skeletal function, and health-related quality of life in breast
cancer survivors. Our results advocate the need to define tailored
physical exercise interventions that could be performed in
common clinical practice as a first-line rehabilitative treatment
to reduce BCF.
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